Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. reduced its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 7.5% in the 4th quarter, HoldingsChannel reports. The fund owned 4,240 shares of the biopharmaceutical company’s stock after selling 342 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Halozyme Therapeutics were worth $204,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Congress Asset Management Co. lifted its stake in Halozyme Therapeutics by 446.5% during the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after purchasing an additional 1,988,238 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in Halozyme Therapeutics by 698.8% during the fourth quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock worth $13,756,000 after purchasing an additional 251,711 shares in the last quarter. Boston Trust Walden Corp lifted its position in shares of Halozyme Therapeutics by 54.0% during the 3rd quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock worth $39,073,000 after buying an additional 239,321 shares during the last quarter. South Street Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at $9,812,000. Finally, Hantz Financial Services Inc. acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at $9,260,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 2.40% of the company’s stock.

Analyst Upgrades and Downgrades

HALO has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $70.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, February 4th. JMP Securities lifted their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Piper Sandler upped their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Wells Fargo & Company dropped their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Finally, Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.89.

Halozyme Therapeutics Trading Up 0.9 %

Shares of HALO stock opened at $58.61 on Friday. The company has a market capitalization of $7.46 billion, a P/E ratio of 19.41, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The business’s 50 day moving average is $52.09 and its two-hundred day moving average is $54.45. Halozyme Therapeutics, Inc. has a twelve month low of $34.70 and a twelve month high of $65.53.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.